{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:59:44Z","timestamp":1789516784218,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>There has been an increase in research on the topic of psychedelic substances and their effects as treatment options in neuropsychiatric conditions. Psilocybin is a psychedelic drug that has recently garnered increased interest as an effective treatment modality for treatment-resistant depression, depression associated with terminal conditions, certain substance use disorders, and obsessive-compulsive disorder. However, sparse data exist as to the effects that psilocybin might have on patients at risk for mania, in large part secondary to the exclusion of this patient population from studies due to the concern for inducing mania or worsening illness course. We describe a case of a 21-year-old male with a recent diagnosis of bipolar II disorder who developed a manic episode following the ingestion of psilocybin in the form of hallucinogenic mushrooms. Given the incidence of depression in those with bipolar disorder, impulsivity, and a tendency to abuse substances associated with the illness, further research is needed into the risks of psilocybin and other psychedelic use in those with bipolar disorder.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1221131","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T09:59:09Z","timestamp":1695376749000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Manic episode following psilocybin use in a man with bipolar II disorder: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Haniya J.","family":"Halim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley G.","family":"Burk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Fargason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badari","family":"Birur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/molecules26102948","article-title":"The therapeutic potential of psilocybin","volume":"26","author":"Lowe","year":"2021","journal-title":"Molecules"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/02791072.2017.1344898","article-title":"A Physician's attempt to self-medicate bipolar depression with N,N-dimethyltryptamine (DMT)","volume":"49","author":"Brown","year":"2017","journal-title":"J Psychoactive Drugs"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/ijms17111953","article-title":"D-lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology","volume":"17","author":"De Gregorio","year":"2016","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.npp.1300819","article-title":"Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex","volume":"31","author":"Pehek","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"100240","DOI":"10.1016\/j.jadr.2021.100240","article-title":"Evaluating the risk of psilocybin for the treatment of bipolar depression: a review of the research literature and published case studies","volume":"6","author":"Gard","year":"2021","journal-title":"J Affect Disord Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/02698811221131997","article-title":"Risks and benefits of psilocybin use in people with bipolar disorder: an international web-based survey on experiences of 'magic mushroom' consumption","volume":"37","author":"Morton","year":"2023","journal-title":"J Psychopharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40345-014-0020-y","article-title":"Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report","volume":"3","author":"Szmulewicz","year":"2015","journal-title":"Int J Bipolar Disord"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bdi.13095","article-title":"An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: a case report","volume":"23","author":"Hendin","year":"2021","journal-title":"Bipolar Disord"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1177\/070674371005500802","article-title":"The early natural history of bipolar disorder: what we have learned from longitudinal high-risk research","volume":"55","author":"Duffy","year":"2010","journal-title":"Can J Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1221131\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T09:59:17Z","timestamp":1695376757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1221131\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":17,"alternative-id":["10.3389\/fpsyt.2023.1221131"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1221131","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"article-number":"1221131"}}